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Abstract
Background: Enhanced eosinophil responses have critical roles in the development of allergic diseases. IL-5 regulates the
maturation, migration and survival of eosinophils, and IL-5 and eotaxins mediate the trafficking and activation of eosinophils
in inflamed tissues. CD4+ Th2 cells are the main producers of IL-5 and other cells such as NK also release this cytokine.
Although multiple signalling pathways may be involved, STAT6 critically regulates the differentiation and cytokine
production of Th2 cells and the expression of eotaxins. Nevertheless, the mechanisms that mediate different parts of the
eosinophilic inflammatory process in different tissues in allergic airway diseases remain unclear. Furthermore, the
mechanisms at play may vary depending on the context of inflammation and microenvironment of the involved tissues.
Methodology/Principal Findings: We employed a model of allergic airway disease in wild type and STAT6-deficient mice to
explore the roles of STAT6 and IL-5 in the development of eosinophilic inflammation in this context. Quantitative PCR and
ELISA were used to examine IL-5, eotaxins levels in serum and lungs. Eosinophils in lung, peripheral blood and bone marrow
were characterized by morphological properties. CD4+ T cell and NK cells were identified by flow cytometry. Antibodies
were used to deplete CD4+ and NK cells. We showed that STAT6 is indispensible for eosinophilic lung inflammation and the
induction of eotaxin-1 and -2 during allergic airway inflammation. In the absence of these chemokines eosinophils are not
attracted into lung and accumulate in peripheral blood. We also demonstrate the existence of an alternate STAT6-
independent pathway of IL-5 production by CD4+ and NK cells that mediates the development of eosinophils in bone
marrow and their subsequent movement into the circulation.
Conclusions: These results suggest that different points of eosinophilic inflammatory processes in allergic airway disease
may be differentially regulated by the activation of STAT6-dependent and -independent pathways.
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Introduction
Eosinophilic inflammation is a hallmark feature of allergic
diseases of the lung (asthma), gastrointestinal tract (allergic
eosinophilic gastroenteritis), skin (eczema), other systemic diseases
(idiopathic hypereosinophilic syndrome and eosinophilic pneumo-
nia) and parasitic helminth infection [1]. Eosinophils play an
important pathogenetic role in the processes that lead to the
precipitation of these diseases by releasing a wide range of
cytotoxic products and proinflammatory factors [1,2]. A substan-
tial body of research has elucidated the major molecular processes
that regulate the development of eosinophilic inflammation.
Eosinophils differentiate in the bone marrow from pluripotent
stem cells and IL-3, IL-5 and GM-CSF are particularly important
factors that promote their development [1,3].
IL-5 is the most important factor that regulates the expansion,
growth and survival of eosinophils although it is dispensable for
eosinophil development under homeostatic conditions [4]. This
cytokine also directly promotes allergic airway disease by
mediating eosinophilic inflammation [5]. Indeed many diseases
that have accompanying eosinophilic inflammation are often
associated with increased expression of IL-5 [6]. Importantly, this
cytokine provides a critical signal for the eosinophilic response in
bone marrow and the subsequent release of this cell into
peripheral blood in response to inflammatory stimulation [5,7].
Mice deficient in IL-5 have reduced numbers of eosinophils in
peripheral blood and bone marrow and mice over-expressing IL-5
have increased infiltrations of eosinophils into many tissues (e.g.
spleen, bone marrow, lung and lymph nodes) [4,8]. Nevertheless,
the cellular and molecular mechanisms that mediate the
production of IL-5 and the subsequent development of eosino-
philic responses have not been fully elucidated.
Once eosinophils are produced specific chemotactic factors,
namely the chemokines eotaxin-1, -2 and -3, cooperate with IL-5
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to critically regulate their migration and activation during allergic
inflammation [1]. These chemokines possess common biologic
functions but regulate different phases of eosinophil recruitment
during allergic inflammation in humans, although only eotaxin-1
and -2 have been identified in mice [1]. Eotaxins also induce rapid
and transient actin polymerization, upregulate integrin function,
and modulate respiratory burst in eosinophils [1].
Many immune cells, in particular CD4+ T-helper type 2
lymphocytes (Th2 cells), CD8+ T cells, and NK cells but also mast
cells and eosinophils produce IL-5. Of these cells, Th2 cells are the
predominant source of IL-5 during allergic responses [9–11]. NK
cells have also been demonstrated to secrete IL-5 and actively
regulate the development of eosinophilic inflammation in human
and animal studies [9,12]. Although NK cells are well known to
critically regulate both Th1 and Th2 responses [13], their roles in
the regulation of eosinophilic responses in bone marrow during
allergic inflammation remains incompletely understood.
Clinical and experimental investigations have demonstrated the
obligatory role of Th2 cells in the pathogenesis of eosinophilic
inflammation and allergic disorders [14–16]. STAT6 is a critical
factor for efficient Th2 polarization [17,18] and the expression of
eotaxins [19–21]. Indeed, STAT6-deficient mice do not develop
AHR or eosinophilic airway inflammation in mouse models of
allergic airway disease [22–24]. By contrast, in other systems,
STAT6 is not required for tissue eosinophilia [25,26]. Further-
more, there is evidence that STAT6-independent IL-5 production
is involved in eosinophilic inflammation of the intestine during
Nippostrongylus brasilliensis infection in mice [27]. The role of
STAT6 in different parts of the eosinophilic inflammatory
processes in allergic airway disease is not understood. Further-
more, the contribution and roles of STAT6 in mediating the
production of IL-5 and eotaxins and in the development of
eosinophils in the bone marrow, their release into blood and in the
progression of eosinophilic inflammation remains poorly charac-
terized.
In this study we assessed the role of STAT6 in the development
of eosinophilic inflammation in a mouse model of allergic airways
inflammation using wild type (WT) and STAT6-deficient mice.
We also determined the roles of IL-5, eotaxins, CD4+ and CD8+ T
cells and NK cells in the development of STAT6-independent
eosinophilic inflammation.
Materials and Methods
Animals
Specific pathogen free WT and STAT6-deficient BALB/c mice
(male and female, 6–8 weeks) were obtained from the University of
Newcastle and Australian National University. STAT6-deficient
mice were backcrossed for 12 generations onto the BALB/c
background. All experiments were performed with approval from
the animal ethics committees of The University of Newcastle (ID
899 and 974) and the Australian National University (The early
part of experiments was conducted at ANU and ANU ID was
expired and not archived).
Induction of allergic airways inflammation
Mice were sensitized at 6–8 wk of age by i.p. injection (day 0)
with 50 mg of ovalbumin (OVA) (fraction V, Sigma, St Louis, MO,
USA) admixed with 1 mg Alhydrogel (Reheis Inc., Berkeley
Heights, NJ, USA) in 200 ml of 0.9% sterile saline on day 0 and 12.
Non-sensitized mice were injected with 1 mg Alhydrogel in 200 ml
of 0.9% sterile saline. On days 24, 26, 28 and 30, all groups of
mice were challenged with aerosolized OVA (10 mg/ml in 0.9%
saline) for 3630 minutes with 30 minutes break using an ultrasonic
nebuliser. On day 23, 25, and 27, 29 and 31, eosinophils as a
percentage of leukocytes in peripheral blood were assessed. On
day 31 inflammatory responses in bronchoalveolar lavage, airway
sections and lung tissue, and eosinophil numbers in the bone
marrow were assessed as previously described [28–30].
Bronchoalveolar lavage and histopathology
Bronchoalveaolar lavage was collected, cells isolated and stained
and differential inflammatory cell counts performed as previously
described [30]. Lungs were fixed in 10% phosphate-buffered
formalin, sectioned, and stained with carbol chromotrope and
eosinophils enumerated as previously described [31].
ELISA Analysis
Blood was collected by heart bleed and cell-free serum
prepared. IL-5, eotaxin-1 and -2 were determined by ELISA
cytokine according to the instructions of the manufacturer (BD
Pharmingen, San Diego, CA, USA) [30].
Quantitative PCR
The method for quantitative PCR has been described in detail
previously [32]. Briefly, RNAwas prepared from cells or tissue using
the TRIzol RNA isolation buffer following the protocol of the
manufacturer (Invitrogen Life Technologies). cDNA was synthe-
sized by an oligo(dT) primed reverse transcriptase reaction using
0.5 mg of RNA from each sample. Quantitative PCR was
performed using an ABI PRISM 7000 Sequence Detection System
(Applied Biosystems) using the following primers: murine IL-5
(forward, CTCTGTTGACAAGCAATGAGACG and reverse,
TCTTCAGTATGTCTAGCCCCTG); eotaxin-1 (forward, CCC-
AACACACTACTGAAGAGCTACAA, and reverse, TTTGCC-
CAACCTGGTCTTG); eotaxin-2 (forward, TAGCCTGCGCG-
TGTTGCATCTTCC, and reverse, TAAACCTCGGTGCTAT-
TGCCACGG); and GAPDH (forward, CAGGTTGTCTCC-
TGCGACTT, and reverse, CCCTGTTGCTGTAGCCGTA).
SYBR-green was used to detect changes in amplicon levels with
each sequential amplification cycle. The fluorescence intensity was
normalized to the rhodamine derivative ROX as a passive reference
label, which was present in the buffer solution. The level of mRNA,
normalized to GAPDH, was calculated as fold change.
Flow cytometry
Bone marrow was isolated as previously described [33]. Samples
were dissociated into single cell suspensions, and depleted of
erythrocytes using 0.86% (w/v) ammonium chloride. Cells were
washed and stained for surface marker expression using fluores-
cent monoclonal antibodies. Anti-CD3, anti-CD4 and anti-CD8
(Biolegend, San Diego, CA, USA) were used to detect CD4+ or
CD8+ T cells and anti-CD3, anti-CD49b and anti-FceRII
(Biolegend) were used to detect NK cells (CD32CD49b+FceRII2).
All samples were analysed using a FACSCanto flow cytometer and
associated software (BD Bioscience, San Jose, CA, USA).
Depletion of IL-5, CD4+ and CD8+ T cells and NK cells
Mice were injected i.p. with anti-IL-5 (200 ug, TFK5, rat anti-
mouse monoclonal IgG1, ATCC, Manassas, VA, USA) or isotype
control (rat IgG1) monoclonal antibody (mAb) on days 22, 26 and
30 during the OVA challenge as previously described [34].
Depletion of IL-5 was confirmed in serum samples by ELISA.
CD4+ or CD8+ cells were depleted by i.p. injection with 500 mg
anti-CD4 (Clone GK1.5, rat anti-mouse monoclonal IgG2b) [35]
or anti-CD8 (Clone YTS169.4, rat anti-mouse monoclonal IgG2b)
mAbs [36] or the corresponding isotype control (rat IgG2b), on
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days 22, 26 and 30. Depletion of CD4+ or CD8+ T cells was
confirmed in spleens by FACS analysis.
NK cells were depleted by i.v. injection with 50 ml anti-ASIALO
GM1 polyclonal antibody (Wako Chemicals, Osaka, Japan) or
rabbit serum on day 22, 26 and 30, according to manufacturer’s
instructions as previously described [37]. Depletion of NK cells was
determined in spleens by FACS analysis. In some experiments, both
CD4+ cells and NK cells were depleted by combined treatment with
anti-CD4 and anti-ASIALO GM1 antibodies.
Data analysis
An initial one-way analysis of variance (or a Kruskal-Wallis test
for non-parametric data) was followed by appropriate comparisons
to test for differences between means of groups. Values are
reported as the mean 6 SEM for each experimental group. The
number of mice in each group ranged from 8–12. Differences in
means were considered significant if P,0.05.
Results
STAT6 is required for the influx of eosinophils into the
lungs during allergic airway inflammation
We first investigated the role of STAT6 in eosinophil
accumulation in the lung. WT and STAT6-deficient mice were
sensitized and challenged with OVA/OVA or SAL/OVA and
leukocyte numbers were determined in the BALF. Pronounced
infiltrations of inflammatory cells were detected in the BALF of
OVA/OVA treated WT mice, compared to SAL/OVA treated
controls (Figure 1A). In particular, the levels of eosinophils were
substantially increased (20 fold). By contrast, the numbers of
eosinophils in OVA/OVA treated STAT6-deficient mice were not
significantly increased compared to SAL/OVA treated controls,
and were similar to those in SAL/OVA treated WT mice.
Neutrophils in OVA/OVA treated STAT6-deficient mice were
increased compared to SAL/OVA treated controls but were
significantly decreased compared to OVA/OVA treated WT
mice. The infiltrations of lymphocytes and macrophages were
increased and were similar in both OVA/OVA treated WT and
STAT6-deficient groups.
Histological examination of lung tissue showed that a significant
infiltration of eosinophils occurred into the peribronchial and
perivascular regions of OVA/OVA treated WT mice compared to
SAL/OVA treated controls (Figure 1B). Consistent with the
observations in BALF, eosinophil accumulation in lung tissue was
absent in OVA/OVA treated STAT6-deficient mice, and was
similar to that in SAL/OVA treated WT mice. These results
demonstrate that STAT6 is required for eosinophilic inflammation
in the lung.
Deficiency in STAT6 results in enhanced eosinophil
accumulation in peripheral blood but impaired
development in bone marrow
To determine the point of the inflammatory pathways where
eosinophil influx in the lung was disrupted in STAT6-deficient
Figure 1. Characterization of eosinophilic inflammation in allergic lungs. OVA/OVA treated WT mice had significantly increased numbers of
eosinophils in (A) BALF and (B) peribronchial and perivascular regions of the lung, compared to SAL/OVA treated controls. The levels of BALF
neutrophil in OVA/OVA treated STAT6-deficient mice were significantly higher than that in SAL/OVA WT control but less than that in OVA/OVA
treated WT mice. No significant infiltration of eosinophils was observed in OVA/OVA treated STAT6-deficient mice, which were at the same levels as
SAL/OVA treated WT mice. #P,0.05 compared to SAL/OVA treated WT, *P,0.05 compared to OVA/OVA treated WT mice.
doi:10.1371/journal.pone.0017766.g001
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mice, eosinophil levels in the blood and bone marrow were
assessed. The percentages of eosinophils in peripheral blood of
OVA/OVA treated WT and STAT6-deficient mice were
significantly greater than in respective SAL/OVA treated controls
(Figure 2A). In the absence of STAT6, there was an increase in the
accumulation of eosinophils in peripheral blood in response to
OVA/OVA treatment compared to WT mice. No increase of
eosinophil percentages in the blood was observed in SAL/OVA
treated WT or STAT6-deficient mice.
OVA/OVA treatment of WT and STAT6-deficient mice
resulted in increased numbers of eosinophil in bone marrow
compared to the respective SAL/OVA controls (Figure 2B). The
number of eosinophils in the bone marrow of OVA/OVA treated
STAT6-deficient mice was significantly lower than in OVA/OVA
treated WT mice. Eosinophils numbers in SAL/OVA treated WT
and STAT6-deficient mice were not significantly different.
STAT6 contributes to IL-5 production and is required for
the expression of eotaxins
IL-5 and eotaxins are critical regulators of the expansion and
chemotaxis of eosinophils [38]. Therefore, we assessed whether the
lack of eosinophilic inflammation in the absence of STAT6
resulted from reduced IL-5 or eotaxin responses. OVA/OVA
treatment of WT mice increased the levels of IL-5 in serum
compared to SAL/OVA controls (Figure 3A). OVA/OVA
treatment of STAT6-deficient mice also increased IL-5 levels
but to a lower level than in WT mice. No increased levels of
eotaxin-1 and -2 were detected in the serum of all groups
(unpublished data). OVA/OVA treatment of WT mice profound-
ly increased the mRNA expression of IL-5, eotaxin-1 and -2 in
lung tissues (Figure 3B–D). Levels of IL-5 in the lung of OVA/
OVA treated STAT6-deficient mice were markedly decreased
compared to OVA/OVA treated WT mice but were still
significantly higher than that of respective SAL/OVA group
(Figure 3B). However, no increase of eotaxin-1 and -2 was
observed in OVA/OVA treated STAT6-deficient mice or SAL/
OVA treated controls. These results indicate that STAT6 does
contribute to IL-5 production and eosinophil accumulation in the
lung tissue. However, IL-5 production and eosinophil develop-
ment and influx into peripheral blood may also occur via a
STAT6-independent pathway. These results also suggest that
STAT6-dependent production of eotaxins is required for the
influx of eosinophils into lung tissue.
STAT6-independent IL-5 production contributes to
eosinophil accumulation in peripheral blood and
development and expansion in bone marrow
We then assessed whether the accumulation of eosinophils in
blood and development in bone marrow in the absence of STAT6
was associated with the STAT6-independent production of IL-5.
OVA/OVA treated STAT6-deficient mice were administered IL-
5 neutralizing mAb or isotype control every four days from day
22 d of the OVA/OVA treatment regime. Anti-IL-5 mAb
treatment completely abolished the increases in the percentage
of eosinophils in the peripheral blood of OVA/OVA treated
STAT6-deficient mice (Figure 4A). The hematopoietic expansion
of eosinophils in bone marrow in OVA/OVA treated STAT6-
deficient mice was also completely abolished by neutralization of
IL-5 (Figure 4B). Thus, STAT6 independent IL-5 production
mediates eosinophil accumulation in the blood and development
in bone marrow.
CD4+ cells and NK cells cooperatively regulate the STAT6-
independent development of eosinophils in bone
marrow
CD4+- and CD8+-T cells and NK cells produce IL-5 and may
regulate the expansion of eosinophils in bone marrow. Therefore,
we then assessed the contribution of these cells on the STAT6-
independent development of eosinophils. OVA/OVA treated
STAT6-deficient mice were administered CD4+, NK, CD4+/NK
or CD8+ cell neutralizing antibodies or isotype control every four
days from day 22 d of the OVA/OVA treatment regime. Some
studies have suggested that anti-ASIALO GM1 antibody may
target other cells (e.g. CD8+ T cells or NK cells) [39,40], however,
many other investigations have found that this antibody
specifically neutralizes NK cells without affecting other cells [41–
43]. We have assessed the specificity and efficacy of NK cell
depletion in our models. This was achieved by examining the
levels of NK cells in the spleens of animals treated with anti-
ASIALO GM1 antibody one day after the last OVA aero-
challenge. The frequency of NK cells was 0.360.25% (mean 6
SEM) compared with 4.160.5% (mean 6 SEM) in isotype-treated
Figure 2. Eosinophil levels in peripheral blood and bone marrow. OVA/OVA treatment of WT and STAT6-deficient mice significantly
increased (A) levels of eosinophils as percentages of leukocytes in peripheral blood and (B) numbers of eosinophils in bone marrow compared to SAL/
OVA treated controls. OVA/OVA treated STAT6-deficient mice had a greater percentage of eosinophils in peripheral blood but significantly fewer
eosinophils in the bone marrow than OVA/OVA treated WT controls. #P,0.05 compared to other groups. *P,0.05 compared to SAL/OVA treated
controls.
doi:10.1371/journal.pone.0017766.g002
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animals. By contrast, the frequency of NKT cells, CD4+ and
CD8+ T cells remained unchanged. This indicates that NK cells,
but not NKT or T cell populations, were specifically depleted [41–
43]. Depletion of CD4+ cells and NK cells significantly reduced
the numbers of eosinophils in the bone marrow of OVA/OVA
treated STAT6-deficient mice, however, numbers were still
greater than in SAL/OVA treated controls (Figure 5A and B).
However, importantly, combined treatment of antibodies against
CD4 and NK cells completely abolished the increase in the
numbers of eosinophil in the bone marrow of OVA/OVA treated
STAT6-deficient mice, which were similar to the levels in SAL/
OVA controls (Figure 5C). Furthermore, the increase in IL-5 was
abolished by the combined administration of anti-CD4 and anti-
NK cell antibodies (5.660.6 pg/ml, data expressed as mean 6
SEM, n=6, P,0.05), compared to isotype control (5960.8 pg/
ml), anti-CD4 (32.760.6 pg/ml) or anti-NK cell (34.360.4 pg/
Figure 3. The levels of IL-5 in serum and expression of eotaxin-1 and -2 mRNA in lungs. OVA/OVA treated WT mice had significantly
increased levels of (A) serum IL-5 and mRNA encoding (B) IL-5, (C) eotaxin-1 and (D) eotaxin-2 in lung tissue compared to SAL/OVA treated controls.
OVA/OVA treated STAT6-deficient mice also had significantly increased levels of IL-5 in serum and lung but these levels were lower than OVA/OVA
treated WT mice. There was no increase the expression of eotaxin-1 and -2 in OVA/OVA treated STAT-6 deficient or SAL/OVA treated controls.
#P,0.05 compared to other groups. *P,0.05 compared to respective SAL/OVA treated control.
doi:10.1371/journal.pone.0017766.g003
Figure 4. The effects of neutralization of IL-5 on eosinophil levels in peripheral blood and bone marrow in the absence of STAT6.
The increased (A) percentages of eosinophils in peripheral blood and (B) numbers of eosinophils in bone marrow in response to OVA/OVA treatment
were completely abolished by neutralization of IL-5 with anti-IL-5 antibody in STAT6-deficient mice. #P,0.05 compared to other groups.
doi:10.1371/journal.pone.0017766.g004
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ml) antibodies alone. Indeed the levels were reduced to those in
SAL/OVA treated WT (6.061.3 pg/ml) and STAT6-deficient
mice (5.960.4 pg/ml). Administration of anti-CD8 antibody had
no effect on eosinophil numbers (Figure 5D). These data suggest
that STAT6-independent IL-5 production from CD4+ T cells and
NK cells contributes to the development of eosinophil responses in
allergic airway inflammation.
Discussion
Here we demonstrate that STAT6 is a critical mediator of
eosinophil influx into the lung. However, we also demonstrate that
an alternative pathway that is independent of STAT6 controls the
movement of eosinophils into the blood and partially mediates
their development in the bone marrow during allergic airway
inflammation. These effects were associated with reduced but still
elevated levels of IL-5 in serum and the inhibition of the
expression of eotaxins in the lung. We also show that IL-5
production, most likely from CD4+ and NK cells, may mediate
STAT6-independent eosinophil accumulation in the blood and
development in the bone marrow.
Other studies by Kuperman et al., using STAT6-deficient mice
on a BALB/c background showed only a 50% reduction in
eosinophil influx into the BALF during allergic airway inflamma-
tion [22]. These results are in direct contrast to our own and those
of others that used STAT6-deficient mice on C57BL/6 or B6/129
backgrounds, which had .90% reduction in eosinophil influx
[23,24]. The differences of reduction of eosinophil influx observed
by Kuperman et al., may be due to the differences in sensitization/
challenge regime or mouse strain. By profiling gene transcripts of
lung tissue from mice with two forms of experimental asthma (e.g.
OVA- and Aspergillus-induced models), Zimmermann et al., found
that a large number of genes are uniquely expressed independently
of STAT6, including chemokines, membrane receptors, transcrip-
tional regulators and enzymes [44]. The authors deduced that the
regulation of some genes may be associated with, but are not
necessarily restricted by STAT6 signalling. This study clearly
indicates that alternative STAT6-independent signalling pathways
exist that may contribute to asthma pathogenesis.
In our study, STAT6 deficiency led to reduced levels of
eosinophils in bone marrow (Figure 2B) and IL-5 in serum
(Figure 3A) in response to OVA/OVA treatment. Anti-IL-5
Figure 5. The effects of depletion of CD4+ and CD8+ T cells and NK cells on the development of eosinophils in the bone marrow in
the absence of STAT6. (A) Anti-CD4 and (B) anti-NK cell (anti-ASIALO GM1) antibody significantly suppressed the increased development of
eosinophils in the bone marrow of OVA/OVA treated STAT6-deficient mice. Combined treatment with (C) anti-CD4 and anti-NK antibodies completely
abolished the increased development of eosinophils. By contrast, (D) anti-CD8 antibody had no effect. #P,0.05 compared to other groups. *P,0.05
compared to SAL/OVA treated mice.
doi:10.1371/journal.pone.0017766.g005
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treatment abrogated eosinophil differentiation in bone marrow in
the absence of STAT6 (Figure 4B). These results indicate that
STAT6 deficiency contributes to, but is not essential for IL-5-
induced eosinophil differentiation in the bone marrow. Since
STAT6 is a critical mediator of Th2 responses [17], and therefore
also IL-5 release, it may seem contradictory that eosinophil and
IL-5 responses were detected in the blood and bone marrow in
STAT6-deficient mice with allergic airway inflammation. This
may result from compensatory mechanisms. Interestingly, others
have shown that although IL-5 is not increased in response to
allergen treatment in STAT6-deficient mice it is expressed at basal
levels in the BALF of mice with a B6/129 background [24]. It is
known that the activation of other signalling systems such as
Notch/GATA3 or IL-2R/STAT5 pathways may also induce Th2
polarization and thereby IL-5 production, although in a less
effective manner [45–47]. It is possible that it was the activation of
these pathways that resulted in the STAT6-independent produc-
tion of IL-5 and eosinophil responses and development in our
study. The STAT6-independent production of IL-5 was respon-
sible for the eosinophil development and movement into the blood
since these responses were completely abolished by neutralization
of IL-5. These results are in agreement with previous studies that
i.v. injection of IL-5 (but not eotaxin) promotes the movement of
eosinophils from the bone marrow into the circulation [7,33].
These results confirm the critical role of IL-5 in the mobilization of
the bone marrow pool of eosinophils into the blood.
Characterization of mRNA levels of chemokines in the lung
revealed that the expression of eotaxin-1 and -2 were exclusively
dependent on STAT6. Other chemokines, including MDC,
TECK, TARC, RANTES, MCPs and MIPs were expressed
independently of STAT6 in response to OVA/OVA treatment
(unpublished data). The absence of eotaxin-1 and -2 in the lung,
however, may have prevented the trafficking of eosinophils from
the blood into lung tissue, and resulted in greater numbers of
eosinophils in the circulation. Interestingly, although IL-5 was still
produced in the lung (although markedly decreased) of OVA/
OVA treated STAT6-deficient mice, the levels of eosinophils in
the lung were not increased. These results confirm the importance
of the STAT6-dependent production of these eotaxins and IL-5,
by contrast to other chemokine subfamilies, in the recruitment of
eosinophils to the airways during allergic inflammation.
CD4+ Th2 cells are the predominant cellular sources of IL-5
[5]. However, other cells such as CD8+ T-cells, NK cells and mast
cells also produce this cytokine [48]. The expression of IL-5 by
different cell types is controlled by variety of pathways. These
different cells and pathways may differentially contribute to the
development of eosinophilic responses in different tissue compart-
ments during allergic reactions, which may depend on the timing
and context of inflammatory stimuli and the immune microenvi-
ronment. NK cells produce IL-5 in allergic asthma [9,49].
Interestingly, these cells do not produce IL-5 without IL-4 [49],
suggesting that they need similar initiating signals, to those which
promote Th2 immune responses. CD4+ NKT cells may also have
a critical role in the pathogenesis of asthma and produce IL-5
when co-cultured with CD1d+ antigen presenting cells and IL-2
[50,51]. Thus, both of these cells may contribute to IL-5
expression during acute inflammatory responses and there is
evidence that crosstalk occurs between NK and NKT cells [52].
The depletion of CD4+ cells and NK cells in the absence of
STAT6 inhibited eosinophilic responses in the bone marrow and
the production of IL-5. These results suggest that although STAT6
pathways play a central role in the induction of eosinophilic
responses, other pathways involving CD4+ T cells and NK cells
may also contribute by independently producing IL-5 and
inducing the development of eosinophilic responses in blood and
bone marrow. Indeed increased numbers of NK cells
(CD32CD49b+FceRII2) were detected in the bone marrow of
OVA/OVA treated STAT6-deficient mice (unpublished data).
These results indicate that a cooperative mechanism of STAT6-
independent production of IL-5 may exist in CD4+ cells and NK
cells and highlights the potential differential regulation of
eosinophilic responses that is mediated by the surrounding
inflammatory environment.
In summary, eosinophilic responses in allergic airway inflam-
mation are differentially regulated by the activation of STAT6-
dependent and -independent pathways at different parts of the
inflammatory process. STAT6-dependent pathways critically
regulate eosinophil migration into the lung, that involves the
induction of eotaxin-1 and -2 expression. However, STAT6-
independent IL-5-regulated eosinophilic pathways operate in
blood and bone marrow compartments. These alternative
pathways may be regulated by CD4+ and NK cells which produce
IL-5 and contribute to the development of eosinophils in the bone
marrow and their subsequent release into the blood. Therefore,
therapeutic strategies that inhibit eosinophilia in eosinophil-
mediated diseases should consider both pathways, even though
both pathways are critically dependent on IL-5.
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